


Specifically, claims 44 and 79 incorporate the limitation of original claim 76, and all other claim amendments are made merely for the purpose of cancelling certain claim dependencies.

New claims 92-100 also find support in the specification. These claims cover cells expressing a combination of a CD28 chimeric receptor and either a chimeric receptor having an Fc receptor FcγRIIIA γ, FcγRIIA, or FcγRIIC signalling domain (claim 92 and its dependent claims) or a chimeric receptor having an mb1 signalling domain (claim 93 and its dependent claims). Support for the new claims is found in the specification as follows: Fc receptor chimeric receptors (claim 92 and its dependent claims), at pages 42, 44-45, 54-58, and Figure 12; and mb1 chimeric receptors (claim 93 and its dependent claims), at pages 58-59 and Figure 18.

If there are any charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: 2 February 1999



Karen L. Elbing, Ph.D.
Reg. No. 35,238

Clark & Elbing LLP
176 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045